Related Experiment Video
Updated: Oct 4, 2025

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group
Josephine H Haduong1, Christine M Heske2, Wendy Allen-Rhoades3
1Division of Oncology, Hyundai Cancer Institute, Children's Hospital Orange County, Orange, California, USA.
Abstract:
Children and adolescents with rhabdomyosarcoma (RMS) comprise a heterogeneous population with variable overall survival rates ranging between approximately 6% and 100% depending on defined risk factors. Although the risk stratification of patients has been refined across five decades of collaborative group studies, molecular prognostic biomarkers beyond FOXO1 fusion status have yet to be incorporated prospectively in upfront risk-based therapy assignments. This review describes the evolution of risk-based therapy and the current risk stratification, defines a new risk stratification incorporating novel biomarkers, and provides the rationale for the current and upcoming Children's Oncology Group RMS studies.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Treatment Resistant Cancers
Clinical Trials: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against...
Hazard Ratio
For example, in a clinical trial...

